留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

高血压相关神经内分泌肿瘤:现状与进展

童安莉 李汉忠

童安莉, 李汉忠. 高血压相关神经内分泌肿瘤:现状与进展[J]. 协和医学杂志, 2020, 11(4): 361-364. doi: 10.3969/j.issn.1674-9081.2020.04.001
引用本文: 童安莉, 李汉忠. 高血压相关神经内分泌肿瘤:现状与进展[J]. 协和医学杂志, 2020, 11(4): 361-364. doi: 10.3969/j.issn.1674-9081.2020.04.001
An-li TONG, Han-zhong LI. Neuroendocrine Neoplasias Related to Hypertension: Current Status and Progress[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 361-364. doi: 10.3969/j.issn.1674-9081.2020.04.001
Citation: An-li TONG, Han-zhong LI. Neuroendocrine Neoplasias Related to Hypertension: Current Status and Progress[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 361-364. doi: 10.3969/j.issn.1674-9081.2020.04.001

高血压相关神经内分泌肿瘤:现状与进展

doi: 10.3969/j.issn.1674-9081.2020.04.001
基金项目: 

中国医学科学院医学与健康科技创新工程 2017-12M-1-001

详细信息
    通讯作者:

    李汉忠  电话:010-69152510, E-mail:hzlipumch@163.com

  • 中图分类号: R58

Neuroendocrine Neoplasias Related to Hypertension: Current Status and Progress

More Information
    Corresponding author: LI Han-zhong  Tel: 86-10-69152510, E-mail:hzlipumch@163.com
  • 摘要: 神经内分泌肿瘤(neuroendocrine neoplasia, NEN)较罕见, 部分NEN可分泌过量激素, 引起患者血压升高, 是继发性高血压的重要病因。导致高血压的NEN包括嗜铬细胞瘤/副神经节瘤、垂体生长激素瘤、垂体促肾上腺皮质激素瘤、甲状旁腺腺瘤/腺癌以及异位分泌激素的NEN。此类患者除高血压症状外, 常伴有其他典型临床特征, 但部分患者临床症状并不明显, 需在早期加以识别。近年来, 随着新的核素显像技术等应用于临床, 极大提高了此类疾病的检出率, 使更多患者得到及时诊治。
    利益冲突  无
  • [1] 王连唐, 程嘉骧, 黄世章.内分泌病理学[M].江西:江西科学技术出版社, 2006:253-296.
    [2] 中华医学会内分泌学分会肾上腺学组.嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J].中华内分泌代谢杂志, 2016, 32:181-187. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnfmdx201603002
    [3] Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma:characteristics and treatment[J]. Endocrinol Metab Clin North Am, 2011, 40:295-311. doi:  10.1016/j.ecl.2011.02.002
    [4] 樊华, 李汉忠, 纪志刚, 等.嗜铬细胞瘤/副神经节瘤术中血压骤升的临床特征分析(附单中心219例报告)[J].中华泌尿外科杂志, 2019, 40:267-271. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhmnwk201904007
    [5] Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99:1915-1942. doi:  10.1210/jc.2014-1498
    [6] 景红丽.生长抑素受体显像在嗜铬细胞瘤、副神经节瘤和肿瘤性骨软化症的临床应用研究[D].北京: 中国医学科学院北京协和医院, 2016.
    [7] Janssen I, Blanchet EM, Adams K, et al. Superiority of[68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma[J]. Clin Cancer Res, 2015, 21:3888-3895. doi:  10.1158/1078-0432.CCR-14-2751
    [8] 邓建华, 李汉忠.嗜铬细胞瘤/副神经节瘤基因突变相关遗传综合征[J].协和医学杂志, 2015, 6:161-165. http://d.wanfangdata.com.cn/periodical/xhyx201503001
    [9] Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381:552-565. doi:  10.1056/NEJMra1806651
    [10] Colao A, Grasso LFS, Giustina A, et al. Acromegaly[J]. Nat Rev Dis Primers, 2019, 5:20. doi:  10.1038/s41572-019-0071-6
    [11] Puglisi S, Terzolo M. Hypertension and acromegaly[J]. Endocrinol Metab Clin North Am, 2019, 48:779-793. doi:  10.1016/j.ecl.2019.08.008
    [12] Vilar L, Vilar CF, Lyra R, et al. Acromegaly:clinical features at diagnosis[J]. Pituitary, 2017, 20:22-32. doi:  10.1007/s11102-016-0772-8
    [13] Katznelson L, Laws ER, Melmed S, et al. Acromegaly:an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99:3933-3951. doi:  10.1210/jc.2014-2700
    [14] Zahr R, Fleseriu M. Updates in diagnosis and treatment of acromegaly[J]. Eur Endocrinol, 2018, 14:57-61. doi:  10.17925/EE.2018.14.2.57
    [15] Lloyd RV, Osamura RY, Kloppel G, et al. WHO classification of tumours of endocrine organs[M]. 4th ed. Lyon:International Agency for Research on Cancer, 2017:12-23.
    [16] Trouillas J, Jaffrain-Rea ML, Vasiljevic A, et al. How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020[J]. Cancers (Basel), 2020, 12. pii:E514.doi: 10.3390/cancers12020514.
    [17] Stelmachowska-Banas M, Glogowski M, Vasiljevic A, et al. Ectopic acromegaly due to growth hormone-releasing hormone secretion from bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency[J]. Pol Arch Intern Med, 2019, 129:208-210.
    [18] 中华医学会内分泌学分会.库欣综合征专家共识(2001年)[J].中华内分泌代谢杂志, 2011, 28:96-102.
    [19] Barbot M, Ceccato F, Scaroni C. The pathophysiology and treatment of hypertension in patients with Cushing's syndrome[J]. Front Endocrinol (Lausanne), 2019, 10:321. doi:  10.3389/fendo.2019.00321
    [20] Araujo Castro M, Marazuela Azpiroz M. Two types of ectopic Cushing syndrome or a continuum? Review[J]. Pituitary, 2018, 21:535-544. doi:  10.1007/s11102-018-0894-2
    [21] Isidori AM, Sbardella E, Zatelli MC, et al. Conventional and nuclear medicine imaging in ectopic Cushing's syndrome:A systematic review[J]. J Clin Endocrinol Metab, 2015, 100:3231-3244. doi:  10.1210/JC.2015-1589
    [22] Kalla A, Krishnamoorthy P, Gopalakrishnan A, et al. Primary hyperparathyroidism predicts hypertension:Results from the National Inpatient Sample[J]. Int J Cardiol, 2017, 227:335-337. doi:  10.1016/j.ijcard.2016.11.080
    [23] Graff-Baker AN, Bridges LT, Chen Q, et al. Parathyroidectomy for patients with primary hyperparathyroidism and associations with hypertension[J]. JAMA Surg, 2019, 155:32-39. https://www.ncbi.nlm.nih.gov/pubmed/31596437
    [24] Fisher SB, Perrier ND. Primary hyperparathyroidism and hypertension[J]. Gland Surg, 2020, 9:142-149. doi:  10.21037/gs.2019.10.21
  • 加载中
计量
  • 文章访问数:  440
  • HTML全文浏览量:  66
  • PDF下载量:  70
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-03-27
  • 刊出日期:  2020-07-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!